- Publish by :
- Source: AMSBIO
- Dated: 25 October 2021
AMSBIO has supplied custom Chimeric Antigen Receptor (CAR) -T products to the University of Strathclyde (UoS) in Glasgow, UK, and ScreenIn3D Ltd, enabling them to perform novel immunoassays – Oncology in 3D microfluidic cancer models.
CAR-T cells are genetically engineered T cells used to detect and kill cancer cells by targeting specific cancer-associated proteins, or antigens. CAR-T cell therapy is highly effective against hematologic malignancies, but faces challenges in solid tumors due to the immunosuppressive effects of the tumor microenvironment. Often, combination therapies, such as chemotherapy and checkpoint blocking, are used with CAR-T to improve effectiveness.
To study the efficacy of CAR-T, their off-target cytotoxicity, and their synergistic effects when used in combination assays, researchers at UoS and ScreenIn3D have developed new, miniaturized screening assays that use very small amounts. CAR-T cells in complex in vitro 3D models of solid tumors on a chip.
This exciting technological breakthrough from UoS and ScreenIn3D researchers is described in detail in a recently published technical article – see https://bit.ly/3iASDy0
AMSBIO offers a personalized service that allows researchers to take advantage of the amazing clinical advances made with CAR-T cells in various hematologic malignancies. With its expertise in the development of monoclonal antibodies (rabbit and mouse), AMSBIO can help you design, plan and execute your CAR-T study, whether you are at the preclinical, clinical or proof of concept stage. The AMSBIO CAR-T platform is highly adaptable to your needs and starting materials, allowing you to start with a target molecule (Phase I) or an antibody (Phase II). As part of its custom CAR-T development service, AMSBIO constructs the single-chain variable fragment (ScFv), transfers it into a CAR lentivector of your choice, makes a lentivirus, and transduces activated human (or mouse) T cells. . After CAR-T cell proliferation, cytotoxicity is measured in a real-time assay, CAR expression analyzed and cytokine production quantified. For more information please visit https://www.amsbio.com/car-t-cell-research/ or contact AMSBIO at + 44-1235-828200 / + 1-617-945-5033 / [email protected]
Founded in 2018 – ScreenEn3D is a start-up based at the Center for Technology and Innovation at the University of Strathclyde, UK. ScreenIn3D uses the latest advances in microfluidics and 3D culture to develop a unique microfluidic screening platform. Thanks to its proprietary ONCO-Chip 3D technology, ScreenIn3D is able to offer high quality preclinical screening services to biotechnology and pharmaceutical companies interested in the development of new oncology tests. For more information please visit https://screenin3d.com/
Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading transatlantic company contributing to the acceleration of discovery through the provision of cutting-edge life science technologies, products and services for research. and development in the medical, nutritional, cosmetic and energy fields. Industries. AMSBIO has deep expertise in extracellular matrices to provide elegant solutions to study cell motility, migration, invasion and proliferation. This expertise in cell culture and ECM allows AMSBIO to partner with clients to customize cell systems to improve organoid and spheroid screening results using a variety of 3D culture systems, including organ-on-chip microfluidics. For drug discovery research, AMSBIO offers assays, recombinant proteins and cell lines. Relying on a large and comprehensive biodepot, AMSBIO is widely recognized as one of the leading suppliers of high quality tissue samples (including custom sourcing) from human and animal tissues. The Company Provides Unique Clinical Grade Products for Stem Cell and Cell Therapy Applications these include high quality solutions for viral delivery (lentivirus, adenovirus and adeno-associated virus) in addition to GMP cryopreservation technology.